Viewing 0 reply threads
  • Author
    • #17343

      Enrollment is open at sites in the U.S., Canada, and Australia.

      MOVE-FA is a Phase 2/3 interventional study that will monitor the safety and efficacy of the drug Vatiquinone. This 2-year study is sponsored by PTC Therapeutics. Eligibility criteria include:

      -Genetically confirmed FA with two GAA repeat expansions (currently, point mutations and deletions are excluded from the study)
      -Children ages 7-17 and Adults age 18 and older
      -Ability to walk 10 feet in one minute (can use assitive devices of cane or walker; no wheelchair)
      -Be able to swallow capsules
      -Not have participated in another interventional study in the 2 months prior to enrollment in MOVE-FA

      Information on MOVE-FA and contacts for study coordinators can be found below:

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account